Risk Factors Update Summary
- The company needs substantial additional funding for rezafungin and other programs. As of December 31, 2023, cash and cash equivalents were $35.8 million.
- The CCPA allows fines of up to $7,500 per intentional violation, while the CPRA expands compliance costs.
- Collaboration with Janssen for CD388 saw an increase in funding from $25 million to $44 million.
- The CPRA increases potential liability and compliance efforts for personal data maintained about California residents.
- The company faced delisting from Nasdaq due to failure to maintain the Minimum Bid Price Requirement.
- The CPRA and similar laws in other states and countries may complicate compliance efforts.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1610618&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.